BACKGROUND: Red blood cell (RBC) alloimmunization is reported to occur at an incidence
of 5.2% to 23.5% among patients with thalassemia requiring chronic transfusion. With very …

Red blood cell (RBC) transfusions can be life‐sustaining in chronic inherited anaemias,
such as thalassaemia, and the indications for blood transfusions in patients with sickle cell …

BACKGROUND: Alloimmunization after exposure to red cell (RBC) alloantigens depends on
genetic and acquired patient‐related factors, dose and route of administration, and the …

Despite the significance of red blood cell (RBC) alloimmunization, the lack of standardized
registries in the US has prevented the completion of large studies. Data from 3· 5 years of …

BACKGROUND: Red blood cell (RBC) alloimmunization is common in transfused patients.
Most studies report on the rate of alloimmunization in chronically transfused patients, which …

Red blood cell (RBC) transfusion is the primary treatment for severe forms of thalassaemia.
Pre‐storage screening has resulted in decreased transfusion‐transmitted infections, but anti …

Red blood cell (RBC) transfusions are a milestone in the treatment for sickle cell anaemia
(SSA) and for thalassaemia. RBC alloimmunization remains a major challenge of chronic …

BACKGROUND: Red blood cell (RBC) alloimmunization is a major problem in chronically
transfused patients because of the risk of hemolytic reactions and limited availability of …

The development of hemolytic erythrocyte alloantibodies and autoantibodies complicates
transfusion therapy in thalassemia patients. These antibodies ultimately increase the need …

BACKGROUND: It has long been known that relative immunogenicity is a characteristic of
protein red blood cell (RBC) antigens, but the mechanisms remain unclear. The aim of this …